Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Inventory Average (2019 - 2025)

Historic Inventory Average for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $4.0 million.

  • Karyopharm Therapeutics' Inventory Average fell 1495.06% to $4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year decrease of 1495.06%. This contributed to the annual value of $4.4 million for FY2025, which is 1278.59% up from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Inventory Average is $4.0 million, which was down 1495.06% from $4.5 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Inventory Average ranged from a high of $4.9 million in Q2 2025 and a low of $2.9 million during Q1 2021
  • Its 5-year average for Inventory Average is $3.9 million, with a median of $4.0 million in 2021.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Inventory Average soared by 33753.8% in 2021, and later tumbled by 2781.02% in 2024.
  • Over the past 5 years, Karyopharm Therapeutics' Inventory Average (Quarter) stood at $4.0 million in 2021, then rose by 5.27% to $4.2 million in 2022, then dropped by 27.44% to $3.1 million in 2023, then skyrocketed by 53.07% to $4.7 million in 2024, then fell by 14.95% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q4 2025, $4.5 million for Q3 2025, and $4.9 million during Q2 2025.